Observational studyJournal of neurology2026
Stage-specific polysomnographic and MRI markers across phenoconversion in isolated REM sleep behavior disorder.
Observational study in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo identify stage-specific neurophysiological and structural markers across non-converted isolated rapid eye movement (REM) sleep behavior disorder (iRBD), phenoconverted iRBD, and established α-synucleinopathy.
methodsWe retrospectively analyzed 86 patients who underwent video-polysomnography (PSG) and magnetic resonance imaging (MRI), classified at baseline as iRBD or established α-synucleinopathy, with longitudinal follow-up to define non-converted (n = 27), phenoconverted iRBD (n = 25), alongside established α-synucleinopathy (n = 34). Pairwise comparisons assessed stage-specific differences, followed by multivariable logistic regression to identify discriminative features. Trend analyses and Cox models evaluated progressive changes and predictors of phenoconversion.
resultsCompared with non-converters, phenoconverted iRBD showed PSG abnormalities, including higher NREM arousal and periodic limb movements and lower REM-apnea-hypopnea index (AHI), without structural differences. In contrast, α-synucleinopathy showed widespread cortical and limbic atrophy with PSG abnormalities, including reduced N2 sleep and elevated NREM arousal index and heart rate. Logistic regression identified higher NREM arousal index (odds ratio [OR] = 1.08, p = 0.005) and lower REM-AHI (OR = 0.94, p = 0.006) as predictors of phenoconversion. α-Synucleinopathy was distinguished from non-converters by left cingulate and hippocampal atrophy, reduced REM-AHI, and elevated NREM heart rate. Trend analyses demonstrated progressive cortical and limbic atrophy from non-converted iRBD to phenoconverted iRBD and established α-synucleinopathy. In Cox models, lower left cingulate cortex volume (hazard ratio [HR] = 0.77 per IQR, p = 0.018) and higher NREM arousal index (HR = 1.03, p = 0.010) predicted shorter time to phenoconversion.
conclusionsPSG and MRI capture distinct but complementary, stage-dependent processes in iRBD, with PSG reflecting early functional alterations and MRI indexing progressive neurodegeneration, supporting a stage-aware multimodal approach to risk stratification for α-synucleinopathy.
Indexed as
Identifiers
42234173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.